Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on engineering and developing tools for biological automation. Founded in 2018, the company specializes in creating scalable automation solutions for genetic engineering, aiming to enhance efficiency and precision in biological research and applications.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
SeQure DX
Venture Round in 2021
SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Faze Medicines, a pharmaceutical company, develops interventions against driver of disease pathology. It develops small molecule drugs for initial therapeutic focus areas, such as amyotrophic lateral sclerosis and myotonic dystrophy type 1. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation.
The company was founded in 2018 and based in Cambridge, Massachusetts.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.
Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.
Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients with genetically defined diseases, particularly in areas of high unmet medical need. Headquartered in Cambridge, Massachusetts, the company is advancing its lead product candidate, losmapimod, which is currently in a Phase 2b clinical trial for facioscapulohumeral muscular dystrophy, a rare and progressive muscle-wasting disorder. Additionally, Fulcrum is developing FTX-6058, a small molecule aimed at increasing fetal hemoglobin levels in patients with sickle cell disease and β-thalassemia. The company is also engaged in drug discovery efforts targeting conditions such as Duchenne muscular dystrophy, Friedreich ataxia, and α-synucleinopathies, as well as other neurological and pulmonary diseases. Fulcrum has established collaborations with Acceleron Pharma to explore biological targets in pulmonary diseases and with MyoKardia for the development of therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics is committed to delivering innovative solutions for patients facing significant health challenges.
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing gene therapies aimed at treating both rare and prevalent diseases. Established in 2016, the company focuses on conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs an innovative non-viral platform that includes a proprietary high-capacity DNA construct known as closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a scalable, capsid-free manufacturing process. This approach allows for the targeted delivery of genetic materials, including large and multiple genes across various tissues, and enables redosable treatments tailored to individual patient needs. By enhancing access to therapies for rare diseases and addressing more common conditions, Generation Bio aims to provide durable and sustainable treatment options for patients throughout their lives.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
Jounce Therapeutics is a clinical-stage immunotherapy company focused on developing innovative cancer treatments that harness the immune system to target and eliminate cancer cells. The company's lead product, vopratelimab, is a monoclonal antibody currently in Phase II trials for patients with non-small cell lung cancer and urothelial cancer, particularly those who have not responded to PD-1/PD-L1 inhibitors. Additionally, Jounce is advancing several other therapeutic candidates, including JTX-4014, an anti-PD-1 antibody intended for combination therapy, and JTX-1811, which aims to selectively deplete T regulatory cells in the tumor microenvironment. The company also develops JTX-8064, an antibody targeting a receptor on macrophages. Founded in 2013 by experts in immunobiology and cancer research, Jounce Therapeutics is headquartered in Cambridge, Massachusetts, and is committed to improving patient outcomes through its proprietary immunotherapy platform.
Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production.
The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.
Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass.
Blueprint Medicines Corporation focuses on developing small molecule kinase inhibitors aimed at treating genomic drivers in cancers, rare diseases, and enhancing cancer immunotherapy. The company is advancing several key drug candidates, including avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis and other mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, currently in Phase I clinical trials. Additionally, pralsetinib targets RET-altered non-small cell lung cancer and other solid tumors, while BLU-782 is being investigated for fibrodysplasia ossificans progressive. Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines emphasizes the development of personalized cancer therapies by leveraging insights into cancer genomics and utilizing a proprietary chemical library to identify new therapeutic compounds. The company collaborates with various partners, including Clementia Pharmaceuticals and Genentech, to enhance its research and development efforts.
Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in molecular information products that analyze cancer specimens to provide genomic insights for personalized treatment. The company's platform employs proprietary methods to assist physicians in optimizing cancer therapies and supports biopharmaceutical companies in developing targeted treatments and immunotherapies. Its clinical products include FoundationOne for solid tumors, FoundationOne Heme for blood cancers, and several diagnostic assays aimed at specific cancer types, such as Foundation Assay for Circulating Tumor and FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine offers FoundationCORE, a knowledgebase that promotes advancements in oncology. The company engages in strategic collaborations with notable organizations, including F. Hoffmann-La Roche Ltd. and Genentech, to enhance precision medicine and develop companion diagnostics. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.
Spotfire, a product of TIBCO Software, specializes in interactive and visual data analytics applications, enabling users to analyze data effectively. The platform provides tools that allow individuals to identify trends, patterns, and anomalies within data, facilitating better decision-making. TIBCO Software focuses on delivering Fast Data solutions, ensuring that relevant information is accessible in real time for executives, developers, and business users. With a commitment to transforming data into actionable insights, TIBCO has supported thousands of businesses worldwide in integrating their applications and ecosystems, ultimately enhancing their analytical capabilities.